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Abstract The two known mechanisms for telomere mainte-
nance in eukaryocytes are telomerase in telomerase-positive
cells and alternative lengthening of telomeres (ALT) in telomer-
ase-negative cells. We report here that telomere maintenance in
the telomerase-positive human ovarian SKOV-3 cells was not
a¡ected by inhibition of telomerase. For comparison, the e¡ect
of telomerase inhibitors on telomere maintenance in another
telomerase-positive cell line (i.e. human pharynx FaDu cells)
and the telomerase-negative human osteosarcoma Saos-2 cells
was examined. Telomerase activity was measured using a modi-
¢ed telomeric repeat ampli¢cation protocol and telomere length
was measured using a solution hybridization-based method and
£uorescence in situ hybridization. A reverse transcriptase inhib-
itor (3P-azido-deoxythymidine or AZT) and an antisense against
a component of human telomerase RNA (antisense hTR) were
used to inhibit telomerase. FaDu and SKOV-3 cells showed
comparable baseline telomerase activity. Telomerase activity
in both cells was inhibited about equally by AZT (maximal
inhibition of V80%) and by expression of antisense hTR (com-
plete inhibition in SKOV-3 cells and maximal inhibition of
V80% in FaDu cells). However, treatment with telomerase
inhibitors resulted in V50% telomere shortening in FaDu cells
but had no e¡ect on SKOV-3 nor Saos-2 cells. SKOV-3 cells
did not show the characteristic features of ALT (i.e. heteroge-
neous telomere length and promyelocytic leukemia bodies),
whereas these ALT features were observed in Saos-2 cells. Col-
lectively, these results suggest the existence of a telomerase-in-
dependent mechanism of telomere maintenance in the telomer-
ase-positive SKOV-3 cells. 7 2002 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Telomeres are DNA^protein complexes that cap the chro-
mosome ends. Telomeres have multiple functions, including
preventing chromosomes from fusion and degradation (re-
viewed in [1]). In normal somatic cells, the telomere repeats
are shortened progressively after each cell division, due to the
incomplete replication at the telomeric ends. Cell senescence
occurs when the telomeres reach critical length, leading to the
hypothesis that telomere length is the biological clock that
determines the number of divisions and life span of a cell
[2]. The two known mechanisms for telomere maintenance
in eukaryocytes are telomerase in telomerase-positive cells
and alternative lengthening of telomeres (ALT) in telomer-
ase-negative cells.
Most germ-line and stem cells, immortalized cells, and can-
cer cells contain telomerase, a ribonucleoprotein DNA poly-
merase, that adds telomere repeats onto the 3P-ends of chro-
mosomes. Telomerase activity is observed in s 85% of cancer
cell lines and human tumors [3]. Inhibition of telomerase us-
ing an antisense to human telomerase RNA component (anti-
sense hTR) or dominant negative expression of mutant telo-
merase reverse transcriptase (TERT) caused telomere
shortening, cell senescence, apoptosis and chromosome insta-
bility in telomerase-positive cells [4,5]. On the other hand,
ectopic expression of TERT in telomerase-negative human
¢broblasts, retinal epithelial cells and vascular endothelial
cells results in elongation of telomere length, extension of
life span and allowance of cells to bypass the senescence lim-
itation [6^8].
About 15% of human tumors and cancer cell lines do not
express detectable telomerase activity. Telomeres in these cells
are maintained by mechanisms that are independent of telo-
merase, referred to as ALT [9]. For example, studies using
telomerase RNA component-de¢cient mice (mTER3=3) dem-
onstrated a telomerase-independent mechanism for telomere
maintenance and elongation [10]. In yeasts lacking telomerase
activity and in mosquito Anopheles gambiae, telomeres are
maintained by a homologous recombination-based mecha-
nism [11,12]. Drosophila melanogaster and related Dipteran
species maintain their telomere length by transposition of a
set of retroposons [13,14]. The characteristic features of ALT
are highly heterogeneous telomere length, in a range of 6 5 kb
to s 20 kb and the presence of speci¢c promyelocytic leuke-
mia (PML) bodies that are donut-shaped structures in nuclei
initially observed in PML cells [9,15,16]. The ALT-associated
PML bodies are unique, consisting of telomeric DNA and
telomere-binding proteins TRF1 and TRF2, and are univer-
sally present in ALT cells but absent in mortal cells and telo-
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merase-positive cell lines or tumors [15^17]. ALT in human
cells was surmised from their ability to maintain the telomere
length in the absence of telomerase and from the presence of
telomeres with highly heterogeneous lengths [9]. Recently, an
ALT mechanism of telomere-to-telomere recombination was
found in GM847 cells derived from human skin ¢broblasts
[18].
Za¡aroni and colleagues reported that partial inhibition of
telomerase by either peptide nucleic acids or a hammerhead
riboenzyme targeting the hTR did not result in telomere
shortening in the telomerase-positive human melanoma JR8
and M14 cells, and postulated the emergence of activation of
the ALT mechanism as a response to telomerase inhibition
[19,20]. However, these cells did not show the characteristics
of ALT before or after treatments with telomerase inhibitors.
It is also not known whether the residual telomerase activity
was su⁄cient for telomere maintenance in these cells.
We report here that telomere maintenance in the telomer-
ase-positive human ovarian SKOV-3 cells was not a¡ected by
complete inhibition of telomerase. Another telomerase-posi-
tive cell line (i.e. human pharynx FaDu cells) was used as
the positive control, and the telomerase-negative human os-
teosarcoma Saos-2 cells which use the ALT mechanism [9]
was used as the negative control. A reverse transcriptase
and telomerase inhibitor, 3P-azido-deoxythymidine or AZT
[21] and antisense to hTR, were used to inhibit telomerase.
2. Materials and methods
2.1. Chemicals and reagents
Sulforhodamine B, streptolysin O, p-phenylenediamine and bicin-
choninic acid kit for protein determination were purchased from Sig-
ma (St. Louis, MO, USA); polynucleotide kinase, restriction endonu-
cleases (HinfI, HeaIII and HhaI), DNA molecular weight markers III
and V, hygromycin B, G418, isopropyl-L-D-thiogalactopyranoside
(IPTG), cell proliferation ELISA kit (BrdU) and cell death detection
ELISA kit from Roche Molecular Biochemicals (Indianapolis, IN,
USA); cefotaxime sodium from Hoechst-Roussel (Somerville, NJ,
USA); gentamicin from Solo Pak Laboratories (Franklin Park, IL,
USA); minimum essential medium, RPMI1640 medium, fetal bovine
serum (FBS), Lipofectamine1, and colcemid from Life Technologies
(Grand Island, NY, USA); Q-32P-ATP from ICN (Costa Mesa, CA,
USA); and Advantage cDNA Polymerase Mix from Clontech (Palo
Alto, CA, USA). All chemicals and reagents were used as received.
2.2. Cell culture
Human ovarian SKOV-3, pharynx FaDu and osteosarcoma Saos-2
calls were obtained from the American Type Culture Collection
(Rockville, MD, USA). SKOV-3 cells were cultured in McCoy’s me-
dium and FaDu and Saos-2 cells in minimum essential medium. The
media were supplemented with 9% heat-inactivated FBS, 0.1% 10 mM
non-essential amino acids, 2 mM L-glutamine, 90 Wg/ml gentamicin
and 90 Wg/ml cefotaxime sodium. Cells in exponential growth phase
were used for experiments.
SKOV-3, FaDu and Saos-2 cells were continuously treated with
AZT for up to 9 weeks. Each week, the medium was exchanged
and cells were harvested for analysis of telomerase activity and telo-
mere length.
2.3. Telomere length analysis and detection of PML bodies
Telomere length was measured by two methods. The ¢rst method
used a solution hybridization-based analysis to detect the mean length
of the terminal restriction fragments. This method measured both the
amount and length of telomere (i.e. telomere amount and length as-
say, TALA) [22]. In brief, genomic DNA was isolated and 10 Wg of
DNA was digested at 37‡C overnight with 10 U each of HinfI/CfoI/
HeaIII. The oligonucleotide probe (TTAGGG)4 was labeled by Q-32P-
ATP with polynucleotide T4 kinase. 3 ng of the probe was added to
2.5 Wg of DNA solution. After denaturation at 98‡C for 5 min, hy-
bridization was performed at 55‡C overnight. The samples were elec-
trophoresed on 0.7% agarose gel. After drying under vacuum without
heating, the gel was exposed to phosphorimage screen and the result
was analyzed by ImageQuaNT software from Molecular Dynamics
(Sunnyvale, CA, USA).
The second method for telomere length analysis was £uorescence in
situ hybridization (FISH), which detected telomere signal in individ-
ual cells, as described previously [22]. FISH was also used to detect
PML bodies. The £uorescein-labeled peptide nucleic acid (PNA)
probe (CCCTAA)3 was synthesized by PerSeptive Biosystems (Fra-
mingham, MA, USA). We evaluated the telomere length in interphase
and M phase cells. Brie£y, cells were treated with 0.1 Wg/ml colcemid
for 4 h and then harvested. After treatment with hypotonic solution
and ¢xation with acetic acid and methanol, cells were dropped onto
slides, air-dried and stored at 320‡C. Cells were denatured at 80‡C
for 2 min and hybridized to the PNA probe at room temperature for
2 h. Slides were then washed at room temperature with 70% formam-
ide and phosphate-bu¡ered saline (PBS). The chromosomes were
counterstained with propidium iodide and examined under a £uores-
cence microscope. The digital images were analyzed by Scion Image
software (NIH Image for PC).
2.4. Measurement of telomerase activity
Telomerase activity in intact cells was measured using a modi¢ed
quantitative telomeric repeat ampli¢cation protocol (TRAP) [23].
Brie£y, cells were washed twice with PBS solution and reversibly
porated by streptolysin O (5 U/ml) in the presence of TS primer
(2 WM), and dNTP (50 WM) in 100 Wl of serum-free medium at
room temperature for 5 min. The culture medium (900 Wl) containing
10% FBS was added to stop the permeabilization process. The TS
primer that penetrated the cells was extended in situ by intracellular
telomerase by incubation at 30‡C for 30 min. The extended TS primer
was then extracted by CHAPS-based lysis bu¡er, puri¢ed using phe-
nol/chloroform extraction to eliminate polymerase chain reaction
(PCR) inhibitors. The resulting primers were used as the template
for PCR ampli¢cation as described above. The PCR products were
separated by polyacrylamide gel electrophoresis, followed by ethidium
bromide staining and quanti¢cation by GPTools gel analysis software
(Biophotonics, Ann Arbor, MI, USA).
2.5. Inhibition of telomerase by antisense hTR
To construct a recombinant expression vector containing antisense
or sense hTR, a 185 bp hTR fragment, including the telomere tem-
plate sequence in hTR, was obtained by RT-PCR with the primers 5P-
CAGCTGACATTTTTTGTTTGCTCTA-3P and 5P-GGGTTGCGG-
AGGGTGGGCCT-3P. The fragment was cloned into pGEM-T
Easy vector (Promega, Madison, WI, USA). The recombinant plas-
mid was digested using NotI and the resulting 219 bp DNA fragment
was subcloned into the NotI site of the expression vector pOPRSVI/
MCS (LacSwitch1 II Inducible Mammalian Expression System, Stra-
tagene, La Jolla, CA, USA). The clones that expressed antisense and
sense hTR were con¢rmed by sequencing with T7 or T3 promoter
primer (fmol0 DNA Sequencing System, Promega). SKOV-3 cells
were transfected with the Lac repressor vector, pCMVLac (Lac-
Switch1 II Inducible Mammalian Expression System), using Lipofect-
amine. The transfected cells were selected by hygromycin B treatment.
Cells were then transfected with the recombinant operator vector
Fig. 1. Telomerase activity in SKOV-3, FaDu and Saos-2 cells. Te-
lomerase activity (2.0 Wg protein per sample) was detected by the
modi¢ed TRAP. Six replicates for each cell line. M: pBR322/HaeIII
DNA molecular weight marker. NC: negative control using cell ly-
sis bu¡er instead of lysate.
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pOPRSVI/MCS which expressed either antisense or sense hTR. The
transfected cells were selected by treatment with hygromycin B and
G418. The expression of antisense and sense hTR was induced by
IPTG (3 mM). To ascertain the functionality of the antisense hTR
and to rule out the e¡ect of transfection and IPTG treatment, we used
three controls, i.e. parent cells, cells that expressed sense hTR, and
cells transfected with antisense hTR that was not expressed (i.e. with-
out IPTG induction).
2.6. Analysis of AZT concentrations
Changes in AZT concentrations (starting concentration of 100 WM)
in culture medium over time, in the absence or presence of tumor
cells, were analyzed using an enzyme-linked immunosorbent assay
(Neogen, Lexington, KY, USA). Brie£y, 50 Wl each of medium (pre-
diluted 625-fold with the extraction bu¡er), AZT antibody, and horse-
radish peroxidase-conjugated AZT were added to the wells precoated
with protein A and incubated at room temperature for 1 h. After
washing three times, 150 Wl of substrate solution containing tetra-
methylbenzidine and hydrogen peroxide was added to each well and
allowed to stand for 30 min. The absorbance at 650 nm was measured
using a microplate reader. The concentration of AZT was calculated
according to the standard curve constructed by adding known
amounts of AZT to culture medium. The standard curve was linear
between 2 and 200 ng/ml AZT.
3. Results
3.1. AZT concentrations in culture medium
Analysis of AZT in the culture medium showed that AZT
was stable under the experimental conditions. The AZT con-
centrations, after incubation in the absence or presence of
FaDu, Saos-2 and SKOV-3 cells for 3 and 7 days, ranged
from 96T 9% to 105T 16% of the starting concentrations.
3.2. Baseline telomerase activity
FaDu and SKOV-3 cells showed comparable baseline telo-
merase activity (Fig. 1); the activity in SKOV-3 cells was
86.5T 10.5% of the activity in FaDu cells (P=0.12). In agree-
ment with a previous report [9], Saos-2 cells did not show the
characteristic laddering TRAP products. The background sig-
nals obtained from Saos-2 cells were 9.5 T 5.8% of the signals
in FaDu cells.
Fig. 2. Inhibition of telomerase in SKOV-3 and FaDu cells by
AZT. Top panels: Results of intracellular TRAP. M: pBR322/
HaeIII DNA molecular weight marker, NC: negative control ob-
tained using the permeabilization solution without TS primer. Bot-
tom panels: Drug concentration^response curves.
Fig. 3. Inhibition of telomerase in SKOV-3 and FaDu cells by antisense hTR. Lane 0: control cells before transfection. Lanes 1^3, 4^6 and
7^10: cells cultured for 3, 7 and 15 weeks, respectively. Lanes 1, 4, 7: non-transfected control cells. Lanes 2, 5, 8: cells expressing sense hTR
(i.e. with IPTG induction). Lanes 3, 6, 9: cells expressing antisense hTR. Lane 10: cells transfected with antisense hTR without IPTG. Data
are expressed as % of non-transfected control cells harvested at the beginning of the experiment (i.e. data shown in Lane 0).
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3.3. Inhibition of telomerase by AZT
AZT is converted intracellularly to AZTTP, which inhibits
telomerase. Hence, we examined the e¡ect of AZT only in
intact cells. Fig. 2 shows the concentration-dependent telo-
merase inhibition by AZT in SKOV-3 and FaDu cells. In
both cell types, the maximal inhibition was V80% and was
achieved at 100 WM AZT, the highest concentration used in
the experiment. Similar IC50 values were found for SKOV-3
and FaDu cells (2.2 T 1.5 WM and 2.1T 1.3 WM, respec-
tively).
3.4. Inhibition of telomerase by antisense hTR
Fig. 3 shows the e¡ect of antisense hTR on the telomerase
activity in SKOV-3 and FaDu cells. In both cells, inhibition of
telomerase was observed in cells expressing antisense hTR (i.e.
cells transfected with antisense hTR and induced by IPTG)
treatment, whereas no changes were observed in cells express-
ing sense hTR or cells transfected with antisense hTR but
without IPTG induction of antisense expression.
Inhibition of telomerase activity in SKOV-3 and FaDu cells
by antisense hTR progressed with time and reached maximal
levels at 15 weeks. The maximal inhibition in SKOV-3 cells
was greater than in FaDu cells (93.3% vs. 74.1%). The resid-
ual telomerase activity in SKOV-3 after expressing the anti-
sense hTR for 15 weeks was less than the background signal
found in Saos-2 cells, indicating complete telomerase inhibi-
tion in SKOV-3 cells
3.5. E¡ect of telomerase inhibition on telomere length
Fig. 4 shows the e¡ect of telomerase inhibition on telomere
length. Treatment with AZT for up to 9 weeks or with anti-
sense hTR for up to 15 weeks had no e¡ect on the telomere
length in SKOV-3 cells nor Saos-2 cells. In contrast, the same
treatments resulted in signi¢cant telomere erosion in FaDu
cells (i.e. 27.3% by antisense hTR and 18.4% by 10 WM
AZT in 7 weeks).
3.6. Characteristic features of ALT
Fig. 5 compares the morphology of Saos-2 and SKOV-3
cells. Note the presence of donut-shaped PML bodies in the
interphase Saos-2 cells and the presence of heterogeneous
strength of telomere signals in the M phase Saos-2 cells.
The results indicate the variable telomere length. In contrast,
both M phase and interphase SKOV-3 cells showed relatively
homogeneous telomeric signals with no PML bodies in the
nucleus.
Fig. 4. E¡ect of AZT and antisense hTR on telomere length in SKOV-3, Saos-2 and FaDu cells. A: Telomere length in cells treated with AZT
for 7 weeks. B: E¡ect of AZT (100 WM) on telomere length in SKOV-3 cells, as a function of treatment time. Lane 0, control (before AZT
treatment). Lanes 1^8 correspond to AZT treatment for 1^8 weeks. C: E¡ect of antisense hTR in SKOV-3 cells. Lanes 1^3, 4^6 and 7^10 for
samples treated for 3, 7 and 15 weeks, respectively. Lanes 1, 4, 7: non-transfected control cells. Lanes 2, 5, 8: cells expressing sense hTR (i.e.
with IPTG induction). Lanes 3, 6, 9: cells expressing antisense hTR. D: E¡ect of antisense hTR in FaDu cells. Lanes 1^3 and 4^6 for samples
treated for 3 and 7 weeks, respectively. Lanes 1, 4: control FaDu cells. Lanes 2, 5: cells transfected with sense hTR. Lanes 3, 6: cells trans-
fected with antisense hTR. M: Molecular weight markers: VDNA/EcoRI and HindIII for (A), (C) and (D); VDNA/HindIII for (B). Horizontal
bars depict the locations of the average telomere length.
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4. Discussion
Results of the present study show that in the telomerase-
positive human ovarian SKOV-3 tumor cells, inhibition of
telomerase by a reverse transcriptase inhibitor AZT or anti-
sense to hTR did not lead to telomere erosion. Because the
telomerase activity in SKOV-3 cells was completely inhibited
by antisense hTR, the absence of telomere shortening could
not be due to residual telomerase activity. This is further
con¢rmed by the ¢nding that AZT and antisense hTR treat-
ments resulting in the same or lower extent of telomerase in-
hibition caused signi¢cant telomere erosion in other telomer-
ase-positive human pharynx FaDu cells, which showed about
the same baseline telomerase activity compared to SKOV-3
cells. SKOV-3 cells also did not show the characteristics of
ALT, i.e. highly heterogeneous telomere length and presence
of PML bodies, as found in the telomerase-negative Saos-2
cells. The data of AZT stability in culture media rule out AZT
instability as a reason that AZT failed to reduce the telomere
length in SKOV-3 cells.
There is evidence that telomere maintenance may involve
molecules that participate in DNA repair. For example, mu-
tations of ATM homologs that are DNA damage sensors, i.e.
MEC1 and TEL1, in budding yeast resulted in telomere short-
ening and senescence phenotype similar to a telomerase-de¢-
cient strain [24,25]. The involvement of DNA damage sensors
in telomere maintenance raises the possibility that the un-
capped telomeres may transiently resemble double strand
breaks in DNA and thereby invoke the repair process [26].
The two repair processes for double strand breaks are the
homologous recombination which has been observed in
ALT cells and the non-homologous end joining (NHEJ)
which involves the binding of Ku heterodimers to DNA
breaks that acts to protect DNA from degradation and to
stabilize the lesion [26,27]. The Ku protein is present in telo-
mere DNA^protein complex [28]. The loss of MEC1 and
TEL1 functions may a¡ect the ability to recruit Ku from
telomeric heterochromatin to the chromosome terminus,
which in turn a¡ects the chromosome end processing [27].
In addition to Ku, RAD50, XRS2 and MRE11 are also in-
volved in NHEJ in yeast, and mutations in these proteins lead
to telomere shortening, even in the presence of functional
telomerase [26]. It is not known whether NHEJ plays a role
in the telomere maintenance in SKOV-3 cells.
In summary, results of the present study suggest the exis-
tence of a telomerase-independent mechanism for telomere
maintenance in the telomerase-positive SKOV-3 cells.
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